All NEPA doses showed superior overall CR rates compared with PALO ( @ % , @ % , and @ % for NEPA@ , NEPA@ , and NEPA@ , respectively versus @ % PALO ; P < @ ) with the highest NEPA@ dose studied showing an incremental benefit over lower NEPA doses for all efficacy endpoints .